株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病治療薬の世界市場の分析:機会と予測

Global Haemophilia Market - Analysis By Type (Haemophilia A, Haemophilia B), By Treatment (On-Demand, Prophylaxis), By Region, By Country: 2019 Edition, Opportunities and Forecasts 2013-2023

発行 Azoth Analytics 商品コード 798097
出版日 ページ情報 英文 247 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.05円で換算しております。
Back to Top
血友病治療薬の世界市場の分析:機会と予測 Global Haemophilia Market - Analysis By Type (Haemophilia A, Haemophilia B), By Treatment (On-Demand, Prophylaxis), By Region, By Country: 2019 Edition, Opportunities and Forecasts 2013-2023
出版日: 2019年02月28日 ページ情報: 英文 247 Pages
概要

当レポートでは、世界の血友病治療薬市場について調査分析し、統計と情報 (市場規模・シェア・成長要因) のほか、新興動向、主要促進要因、課題と機会、主要企業について、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 戦略的提言

第4章 血友病治療薬の見通し

第5章 世界の血友病治療薬市場:成長率と予測

  • 市場規模:金額別 (実績)
  • 市場規模:金額別 (予測)

第6章 世界の血友病治療薬市場:セグメント別分析

  • タイプ別:内訳
  • 金額別
  • 治療別:内訳
  • 頓用:金額別
  • 予防:金額別

第7章 世界の血友病治療薬市場:地域別分析

  • 地域別:内訳
  • 北米:成長率と予測
  • 北米:国別分析
  • 欧州:成長率と予測
  • 欧州:国別分析
  • アジア太平洋地域:成長率と予測
  • アジア太平洋地域:国別分析
  • その他の地域:成長率と予測
  • その他の地域:国別分析

第8章 世界の血友病治療薬市場力学

  • 市場促進要因
  • 市場抑制要因

第9章 世界の血友病治療薬市場動向

第10章 ファイブフォース分析

第11章 SWOT分析

第12章 サプライチェーン分析

第13章 競合情勢

第14章 政策・規制情勢

第15章 企業プロファイル

  • Bayer
  • Novo Nordisk
  • Pfizer
  • Roche
  • Aptevo Therapeutics
  • Catalyst BioSciences
  • Dimension Therapeutics
  • Shire
  • CSL Behring
  • Alnylam Pharmaceuticals
図表

List of Figures

  • Figure 1: Haemophilia Genetic Inheritance
  • Figure 2: Replacement Therapy for Haemophilia
  • Figure 3: Global Haemophilia Market Size, By Value, 2013-2017 (USD Billion)
  • Figure 4: Global Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion)
  • Figure 5: Age distribution of haemophilia patients in United states, In 2017
  • Figure 6: Number of People With Hemophilia, By Top 5 Countries, 2017
  • Figure 7: Number of People With Bleeding Disorders, Worldwide, By Specific Disease, In 2017
  • Figure 8: Number of People With Hemophilia, Worldwide, By Type, In 2017
  • Figure 9: Usage of Factor VIII (IU Per Capita)*, 2017
  • Figure 10: Usage of Factor IX Per Capita (IU Per Capita)#, 2017
  • Figure 11: United States Blood Plasma Collection, 2013-2016, in Million Liters
  • Figure 12: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
  • Figure 13: Global Expected Healthcare Industry Outlook
  • Figure 14: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 15: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
  • Figure 16: Projected global population aged 60 years & above (In Billions)
  • Figure 17: Global Haemophilia Market Size, By Type, 2017 (In %)
  • Figure 18: Global Haemophilia Market Size, By Type, 2023 (In %)
  • Figure 19: Global Haemophilia A Market, By Value, 2013-2017 (USD Billion)
  • Figure 20: Global Haemophilia A Market, By Value, Forecast, 2018-2023(USD Billion)
  • Figure 21: Global Haemophilia B Market, By Value, 2013-2017 (USD Billion)
  • Figure 22: Global Haemophilia B Market, By Value, Forecast, 2018-2023(USD Billion)
  • Figure 23: Global Haemophilia Market Size, By Treatment, 2017 (In %)
  • Figure 24: Global Haemophilia Market Size, By Treatment, 2023 (In %)
  • Figure 25: Global On-demand Market, By Value, 2013-2017 (USD Billion)
  • Figure 26: Global On-demand Market, By Value, Forecast, 2018-2023(USD Billion)
  • Figure 27: Global Prophylaxis Market, By Value, 2013-2017 (USD Billion)
  • Figure 28: Global Prophylaxis Market, By Value, Forecast, 2018-2023 (USD Billion)
  • Figure 29: Global Healthcare Landscape, By Select Region
  • Figure 30: Global Haemophilia Market Size, By Region, 2017 (%)
  • Figure 31: Global Haemophilia Market Size, By Region, 2023 (%)
  • Figure 32: North America Haemophilia Market Size, By Value, 2013-2017 (USD Billion)
  • Figure 33: North America Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion)
  • Figure 34: North America GDP, 2012-2017 (USD Trillion)
  • Figure 35: North America GDP per capita, current prices, 2013-2023F (In USD)
  • Figure 36: North America, Haemophilia diagnosis among children, 2017 (%)
  • Figure 37: Causes of acquired haemophilia
  • Figure 38: Percentage of patients obtaining blood, In 2017, In North America
  • Figure 39: Annualized healthcare cost per patient with haemophilia
  • Figure 40: North America Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 41: North America Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion)
  • Figure 42: North America Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 43: North America Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion)
  • Figure 44: U.S. Haemophilia Market Size, By Value, 2013-2023 (USD Billion)
  • Figure 45: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
  • Figure 46: Contribution to total national health expenditures in United States, In 2017
  • Figure 47: Percentage of people with Haemophilia A in United States, In 2017
  • Figure 48: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
  • Figure 49: U.S. Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 50: U.S. Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)
  • Figure 51: U.S. Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 52: U.S. Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 53: Canada Haemophilia Market Size, By Value, 2013-2023 (USD Billion)
  • Figure 54: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
  • Figure 55: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 56: Prevalence of bleeding disorder in Canada
  • Figure 57: Usage of clotting factors in Canada, In 2017
  • Figure 58: Canada Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 59: Canada Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)
  • Figure 60: Canada Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 61: Canada Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 62: Europe Haemophilia Market Size, By Value, 2013-2017 (USD Billion)
  • Figure 63: Europe Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion)
  • Figure 64: Per Capita Health Expenditure, By Select Country, 2017 (USD)
  • Figure 65: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
  • Figure 66: Estimated distribution of per patient cost of haemophilia, Europe, In 2017 (EUR)
  • Figure 67: Breakdown of Total Health Expenditure in Europe, 2018 (%)
  • Figure 68: Major Players in Haemophilia Market in Europe
  • Figure 69: Europe Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 70: Europe Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion)
  • Figure 71: Europe Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 72: Europe Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion)
  • Figure 73: U.K Haemophilia Market Size, By Value, 2013-2023 (USD Billion)
  • Figure 74: U.K, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
  • Figure 75: Haemophilia patients in United Kingdom, yearly basis comparison, In number
  • Figure 76: Prevalence of bleeding disorder in United Kingdom, In 2017
  • Figure 77: Usage of clotting factors in United Kingdom, In 2017
  • Figure 78: U.K. Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 79: U.K. Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)
  • Figure 80: U.K. Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 81: U.K. Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 82: Germany Haemophilia Market Size, By Value, 2013-2023 (USD Billion)
  • Figure 83: Usage of clotting factors in Germany, In 2017
  • Figure 84: Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
  • Figure 85: Average annual percent growth in GDP, 2016 (USD)
  • Figure 86: Germany Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 87: Germany Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)
  • Figure 88: Germany Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 89: Germany Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 90: APAC Endoscopy Market Size, By Value, 2013-2017 (USD Billion)
  • Figure 91: APAC Endoscopy Market Size, By Value, Forecast, 2018-2023 (USD Billion)
  • Figure 92: Willingness in countries to donate blood, In 2016
  • Figure 93: World health expenditure as % of GDP
  • Figure 94: APAC, GDP, By Select Country, 2017 (In USD Trillion)
  • Figure 95: Diagnosis and treatment rates of haemophilia in APAC, In Asia, In 2017
  • Figure 96: Disparities in diagnosis of Haemophilia worldwide
  • Figure 97: APAC Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 98: APAC Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion)
  • Figure 99: APAC Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 100: APAC Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion)
  • Figure 101: Japan Haemophilia Market Size, By Value, 2013-2023 (USD Billion)
  • Figure 102: Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 103: Japan Healthcare Expenditure Outlook (%)
  • Figure 104: Prevalence of bleeding disorder in Japan, In 2017
  • Figure 105: Usage of clotting factor in Japan, In 2017
  • Figure 106: Japan Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 107: Japan Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)
  • Figure 108: Japan Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 109: Japan Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 110: India Endoscopy Market Size, By Value, 2013-2023 (USD Billion)
  • Figure 111: Countries with highest rates of haemophilia, In 2017
  • Figure 112: Key factors affecting the Indian Haemophilia Treatment Industry
  • Figure 113: India, Total Population, 2013-2023F (In Billion)
  • Figure 114: India, Share of Urban Population, 2012-2017 (In %)
  • Figure 115: India, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 116: Prevalence of bleeding disorder in India, In 2017
  • Figure 117: India Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 118: India Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)
  • Figure 119: India Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 120: India Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 121: India Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 122: China Healthcare Expenditure Outlook (%)
  • Figure 123: China, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 124: China, Share of Urban Population, 2012-2017 (In %)
  • Figure 125: China, Total Population, 2013-2021F (In Billion)
  • Figure 126: Prevalence of bleeding disorder in China, In 2017
  • Figure 127: Age distribution for haemophilia patients in China, In 2017, In %
  • Figure 128: China Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 129: China Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion)
  • Figure 130: China Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 131: China Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion)
  • Figure 132: ROW Haemophilia Market Size, By Value, 2013-2023 (USD Billion)
  • Figure 133: Middle East and North Africa, GDP, 2012-2017 (In USD Trillion)
  • Figure 134: Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2017 (In %)
  • Figure 135: Top 10 fastest growing economies, 2018, (In%)
  • Figure 136: Percentage of people with haemophilia A in Latin America, In 2017
  • Figure 137: ROW Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 138: ROW Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion)
  • Figure 139: ROW Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 140: ROW Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion)
  • Figure 141: Brazil Haemophilia Market Size, By Value, 2013-2023 (USD Million)
  • Figure 142: Brazil, GDP, 2012-2017 (In USD Trillion)
  • Figure 143: Brazil health expenditure as a share of GDP, 2016
  • Figure 144: Prevalence of bleeding disorder in Brazil
  • Figure 145: Inhibitor formation in hemophiliac patients, In Brazil, In 2017
  • Figure 146: Brazil Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)
  • Figure 147: Brazil Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)
  • Figure 148: Brazil Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)
  • Figure 149: Brazil Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)
  • Figure 150: Working of traditional factors vs. half life factors
  • Figure 151: Bayer, Sales Revenue, 2013-2017 (USD Billion)
  • Figure 152: Bayer, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 153: Bayer , Sales, By Geographic region, FY ended March 2017 (%)
  • Figure 154: Novo Nordisk, Net Sales, 2014-2018 (In Million USD)
  • Figure 155: Novo Nordisk, Net Sales, By Business Sector, 2018 (In %)
  • Figure 156: Novo Nordisk, Net Sales, By Geographic Region, 2018 (In %)
  • Figure 157: Pfizer, Sales Revenue, 2013-2017 (USD million)
  • Figure 158: Pfizer, Sales, By Business Segment, FY ended March 2017 (In %)
  • Figure 159: Pfizer, Sales, By Business Segment, FY ended March 2017 (In %)
  • Figure 160: Pfizer, Sales, By Business Segment, FY ended March 2017 (In %)
  • Figure 161: Roche, Sales, By Business Segment, FY ended March 2018 (%)
  • Figure 162: Roche, By Region, FY ended March 2018 (%)
  • Figure 163: Aptevo Therapeutics, Sales Revenue, 2015-2018 (USD Million)
  • Figure 164: Shire, Sales Revenue, 2016-2017 (USD Million)
  • Figure 165: Shire, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 166: Shire, By Region, FY ended March 2017 (%)

List of Tables

  • Table A: Classification of haemophilia depending upon severity level
  • Table B: Treatment options for Haemophilia
  • Table C: Facts about Haemophilia
  • Table D: Types of Prophylaxis
  • Table E: Prophylaxis over On-demand
  • Table F: Advantages of Prophylaxis
  • Table G: Facts about blood donation in North America
  • Table H: Estimated Haemophilia Insights, In Europe, In 2017
  • Table I: Germany, Healthcare Related Statistics, 2017
  • Table J: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
  • Table K: Coverage of population with health insurance in Latin America, 2017, (In%)
  • Table L: Prevalence of different types of bleeding in haemophilia, In Africa, In 2018
  • Table M: Frequency of hemarthrosis in different joints in South Africa, In 2018, In %
  • Table N: Healthcare spending pattern in Brazil (In USD)
  • Table O: Recent novel gene therapy products for treating Haemophilia
  • Table P: Global Endoscopes Market, By Company Share, 2018 (%)
目次

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Haemophilia Market. The market of Global Haemophilia has been analyzed By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region (North America, Europe, Asia Pacific, Rest of the world) and By Country (U.S, Canada, Germany, U.K, Japan, China, India and Brazil). The Global Haemophilia market has been assessed for the historical period of 2013-2017 and the forecast period of 2018-2023.

According to Azoth Analytics research report "Global Haemophilia Market - Analysis By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region, By Country (2019 Edition): Opportunities and Forecasts (2013-2023) - By Region (North America, Europe, Asia-Pacific, Rest of the World), By Country (U.S, Canada, Germany, United Kingdom, Japan, China, India, Brazil)", the global Haemophilia market is projected to display a modest growth represented by a CAGR of 6.84% during 2018 - 2023.

Over the recent years, global haemophilia market has been witnessing growth, on account of several driving factors including increasing life expectancy of hemophiliac patients, reduction in inhibitor formation in severe haemophilia cases and new emerging therapies for treatment of haemophilia. Moreover, increasing per capita healthcare expenditure and growing incidences of hemorrhages, arthropaedic and dental surgeries, epistaxis, laceration and abrasion is expected to propel the demand for haemophilia market. In this research report, the market is segmented on the basis of type and treatment. By type, the segment of haemophilia A is predicted to hold its dominant position in the market. Amongst the regions, North America accounts for the largest regional share in the global endoscopy devices market in 2018. However, Asia Pacific is predicted to advance at the highest rate. Presence of vast consumer base, particularly in emerging nations such as China and India, in addition to growing per capita expenditure on healthcare is likely to drive the regional market.

The report titled "Global Haemophilia Market, By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region, By Country (2019 Edition): Opportunities and Forecasts (2013-2023) - By Region (North America, Europe, Asia-Pacific, Rest of the World), By Country (U.S, Canada, Germany, United Kingdom, Japan, China, India, Brazil)" has covered and analyzed the potential of global haemophilia market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global haemophilia market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Haemophilia Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Haemophilia Market - Size, Growth, Forecast
  • By Type -Haemophilia A, Haemophilia B
  • By Treatment- On- demand, Prophylaxis

Regional Markets - North America, Europe, Asia-Pacific, ROW (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Haemophilia Market - Size, Growth, Forecast
  • By Type -Haemophilia A, Haemophilia B
  • By Treatment- On- demand, Prophylaxis

Country Analysis - U.S., Canada, Germany, U.K, Japan, India, China, Brazil (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Haemophilia Market - Size, Growth, Forecast
  • By Type -Haemophilia A, Haemophilia B
  • By Treatment- On- demand, Prophylaxis

Other Report Highlights

  • Market Dynamics - Drivers and Restraints
  • Market Trends
  • Company Share Analysis
  • SWOT Analysis
  • Porter Five Force Analysis
  • Supply Chain Analysis
  • Competitive Landscape
  • Policy and Regulatory Landscape
  • Company Analysis - Bayer, Novo Nordisk, Pfizer, Roche, Aptevo Therapeutics, Catalyst BioSciences, Dimension Therapeutics, Shire, CSL Behring, Alnylam Pharmaceuticals .

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Haemophilia Outlook

5. Global Haemophilia Market: Growth and Forecast

  • 5.1 By Value (2013-2017)
  • 5.2 By Value (2018-2023)

6. Global Haemophilia Market: Segment Analysis

  • 6.1 Global Haemophilia Market Size, By Type: Breakdown (%)
    • 6.1.1 Global Haemophilia Market Size, By Type, 2017 (%)
    • 6.1.2 Global Haemophilia Market Size, By Type, 2023 (%)
  • 6.2 Global Haemophilia A Market, By Value (2013-2023)
  • 6.3 Global Haemophilia B Market, By Value (2013-2023)
  • 6.4 Global Haemophilia Market Size, By Treatment: Breakdown (%)
    • 6.4.1 Global Haemophilia Market Size, By Treatment, 2017 (%)
    • 6.4.2 Global Haemophilia Market Size, By Treatment, 2023 (%)
  • 6.5 Global On- demand Haemophilia Market, By Value (2013-2023)
  • 6.6 Global Prophylaxis Market, By Value (2013-2023)

7. Global Haemophilia Market: Regional Analysis

  • 7.1 Global Haemophilia Market Size, By Region : Breakdown (%)
    • 7.1.1 Global Haemophilia Market Size, By Region, 2017 (%)
    • 7.1.2 Global Haemophilia Market Size, By Region, 2023 (%)
  • 7.2 North America Haemophilia Market: Growth and Forecast
    • 7.2.1 By Value (2013-2017)
    • 7.2.2 By Value (2018-2023)
    • 7.2.3 By Type, By Value (2013-2017)
    • 7.2.4 By Type, By Value (2018-2023)
    • 7.2.5 By Treatment, By Value (2013-2017)
    • 7.2.6 By Treatment, By Value (2018-2023)
  • 7.3 North America Haemophilia Market: Country Analysis (U.S and Canada)
    • 7.3.1 U.S Haemophilia Market, By Value (2013-2023)
    • 7.3.2 U.S Haemophilia Market, By Type, By Value (2013-2017)
    • 7.3.3 U.S Haemophilia Market, By Type, By Value (2018-2023)
    • 7.3.4 U.S Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.3.5 U.S Haemophilia Market, By Treatment, By Value (2018-2023)
    • 7.3.6 Canada Haemophilia Market, By Value (2013-2023)
    • 7.3.7 Canada Haemophilia Market, By Type, By Value (2013-2017)
    • 7.3.8 Canada Haemophilia Market, By Type, By Value (2018-2023)
    • 7.3.9 Canada Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.3.10 Canada Haemophilia Market, By Treatment, By Value (2018-2023)
  • 7.4 Europe Haemophilia Market: Growth and Forecast
    • 7.4.1 By Value (2013-2017)
    • 7.4.2 By Value (2018-2023)
    • 7.4.3 By Type, By Value (2013-2017)
    • 7.4.4 By Type, By Value (2018-2023)
    • 7.4.5 By Treatment, By Value (2013-2017)
    • 7.4.6 By Treatment, By Value (2018-2023)
  • 7.5 Europe Haemophilia Market: Country Analysis (U.K and Germany)
    • 7.5.1 U.K Haemophilia Market, By Value (2013-2023)
    • 7.5.2 U.K Haemophilia Market, By Type, By Value (2013-2017)
    • 7.5.3 U.K Haemophilia Market, By Type, By Value (2018-2023)
    • 7.5.4 U.K Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.5.5 U.K Haemophilia Market, By Treatment, By Value (2018-2023)
    • 7.5.6 Germany Haemophilia Market, By Value (2013-2023)
    • 7.5.7 Germany Haemophilia Market, By Type, By Value (2013-2017)
    • 7.5.8 Germany Haemophilia Market, By Type, By Value (2018-2023)
    • 7.5.9 Germany Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.5.10 Germany Haemophilia Market, By Treatment, By Value (2018-2023)
  • 7.6 APAC Haemophilia Market: Growth and Forecast
    • 7.6.1 By Value (2013-2017)
    • 7.6.2 By Value (2018-2023)
    • 7.6.3 By Type, By Value (2013-2017)
    • 7.6.4 By Type, By Value (2018-2023)
    • 7.6.5 By Treatment, By Value (2013-2017)
    • 7.6.6 By Treatment, By Value (2018-2023)
  • 7.7 APAC Haemophilia Market: Country Analysis (Japan, India and China)
    • 7.7.1 Japan Haemophilia Market, By Value (2013-2023)
    • 7.7.2 Japan Haemophilia Market, By Type, By Value (2013-2017)
    • 7.7.3 Japan Haemophilia Market, By Type, By Value (2018-2023)
    • 7.7.4 Japan Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.7.5 Japan Haemophilia Market, By Treatment, By Value (2018-2023)
    • 7.7.6 India Haemophilia Market, By Value (2013-2023)
    • 7.7.7 India Haemophilia Market, By Type, By Value (2013-2017)
    • 7.7.8 India Haemophilia Market, By Type, By Value (2018-2023)
    • 7.7.9 India Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.7.10 India Haemophilia Market, By Treatment, By Value (2018-2023)
    • 7.7.11 China Haemophilia Market, By Value (2013-2023)
    • 7.7.12 China Haemophilia Market, By Type, By Value (2013-2017)
    • 7.7.13 China Haemophilia Market, By Type, By Value (2018-2023)
    • 7.7.14 China Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.7.15 China Haemophilia Market, By Treatment, By Value (2018-2023)
  • 7.8 ROW Haemophilia Market: Growth and Forecast
    • 7.8.1 By Value (2013-2017)
    • 7.8.2 By Value (2018-2023)
    • 7.8.3 By Type, By Value (2013-2017)
    • 7.8.4 By Type, By Value (2018-2023)
    • 7.8.5 By Treatment, By Value (2013-2017)
    • 7.8.6 By Treatment, By Value (2018-2023)
  • 7.9 ROW Haemophilia Market: Country Analysis (Brazil)
    • 7.9.1 Brazil Haemophilia Market, By Value (2013-2023)
    • 7.9.2 Brazil Haemophilia Market, By Type, By Value (2013-2017)
    • 7.9.3 Brazil Haemophilia Market, By Type, By Value (2018-2023)
    • 7.9.4 Brazil Haemophilia Market, By Treatment, By Value (2013-2017)
    • 7.9.5 Brazil Haemophilia Market, By Treatment, By Value (2018-2023)

8. Global Haemophilia Market Dynamics

  • 8.1 Global Haemophilia Market Drivers
  • 8.2 Global Haemophilia Market Restraints

9. Global Haemophilia Market Trends

10. Porter Five Force Analysis

11. SWOT Analysis

12. Supply Chain Analysis

13. Competitive Landscape

14. Policy and Regulatory Landscape

15. Company Profiles

  • 15.1 Bayer
  • 15.2 Novo Nordisk
  • 15.3 Pfizer
  • 15.4 Roche
  • 15.5 Aptevo Therapeutics
  • 15.6 Catalyst BioSciences
  • 15.7 Dimension Therapeutics
  • 15.8 Shire
  • 15.9 CSL Behring
  • 15.10 Alnylam Pharmaceuticals
Back to Top